We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.